Braster

Thermography + AI dx · Breast-cancer detection

Overview

Liquid-crystal thermography device with AI analysis for non-invasive, at-home breast-cancer screening.

What they do

Braster S.A. is a Polish medtech company that develops a liquid-crystal contact-thermography device with AI analysis for non-invasive breast examination. The system pairs a hardware device with a mobile application and a telemedicine platform; the company's BRASTER®PRO version is positioned for use in medical offices, supporting early detection workflows. Its know-how rests on liquid crystals that record and image thermal changes in tissue, a method called liquid-crystal contact thermography, with proprietary AI algorithms trained to detect thermal and structural asymmetries associated with breast cancer.

Lead program & status

The Braster device is the lead product, framed as a complementary, radiation-free screening aid rather than a standalone diagnostic. Between 2013 and 2018 the company reports enrolling roughly 4,700 women across six registration and post-market studies, conducted with Polish gynecological and gynecological-oncology societies. In 2023 Braster launched a mobile screening unit ("Brasterbus"). With grant support from Poland's National Centre for Research and Development (NCBR), the company has planned a further clinical study abroad to validate its automated image-assessment algorithms. Braster has historically been listed on the Warsaw Stock Exchange; thermography's clinical role has drawn debate from some Polish oncologists, which the company has publicly addressed.

Why it matters

A non-invasive, radiation-free, AI-supported screening tool could widen breast-examination access, particularly where mammography is hard to reach - if algorithm performance is validated independently.

FAQ

How does the Braster device work?

It uses liquid-crystal contact thermography to image thermal changes in breast tissue, with AI algorithms flagging thermal and structural asymmetries linked to cancer.

Is Braster a replacement for mammography?

No. It is positioned as a non-invasive, complementary screening aid, not a standalone diagnostic, and its clinical role has been debated among Polish oncologists.

What clinical evidence supports Braster?

The company reports roughly 4,700 women enrolled across six registration and post-market studies (2013-2018) and has planned further abroad validation of its AI algorithms.

Technology

Braster works in AI-Driven Drug Discovery — Compressing years of trial-and-error chemistry into months of computation.

Related companies

Company website / source ↗ Open the interactive map →